{{Infobox drug
| drug_name = 
| IUPAC_name        = 2'-deoxy-P-thioguanylyl-(3'->5')-2'-deoxy-P-thiocytidylyl-(3'->5')-2'-deoxy-P-
thiocytidylyl-(3'->5')-2'-deoxy-P-thiocytidylyl-(3'->5')-2'-deoxy-P-thioadenylyl-(3'->5')-2'-deoxy-P-thioadenylyl-(3'->5')-2'-deoxy-P-thioguanylyl-(3'->5')-2'-deoxy-P-thiocytidylyl-(3'->5')-P-thiothymidylyl-(3'->5')-2'-deoxy-P-thioguanylyl-(3'->5')-2'-deoxy-P-thioguanylyl-(3'->5')-2'-deoxy-P-thiocytidylyl-(3'->5')-2'-deoxy-P-thioadenylyl-(3'->5')-2'-P-thiothymidylyl-(3'->5')-2'-deoxy-P-thiocytidylyl-(3'->5')-2'-deoxy-P-thiocytidylyl-(3'->5')-2'-deoxy-P-thioguanylyl-(3'->5')-2'-P-thiothymidylyl-(3'->5')-2'-deoxy-P-thiocytidylyl (3'->5')-2'-deoxyadenosine
| image             = Alicaforsen.svg
| alt               = 
| caption           = 
<!--Clinical data -->
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A / B            / C / D / X / N -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_NZ = <!--Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status      = 
| routes_of_administration = 
<!--Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       =
| onset             = 
| elimination_half-life = 
| duration_of_action=
| excretion         = 
<!--Identifiers -->
| CAS_number        = 185229-68-9  
| ATCvet            = 
| ATC_prefix        = <!-- 'none' if uncategorised -->
| ATC_suffix        = 
| PubChem           = 16197724
| DrugBank          = 
| ChEMBL            = 2108326
| ChemSpiderID      = 17326145
| synonyms          = DNA, d[(R)-P-thio](G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)
<!--Chemical data -->
| chemical_formula  = 
| C=192 | H=244 | N=75 |O=98 | P=19 | S=19
| molecular_weight  = 6368.171938 g/mol
| smiles            = Cc1cn(c(=O)[nH]c1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=S)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H]9C[C@@H](O[C@@H]9COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1CO)n1cnc2c1nc([nH]c2=O)N)n1ccc(nc1=O)N)n1ccc(nc1=O)N)n1ccc(nc1=O)N)n1cnc2c1ncnc2N)n1cnc2c1ncnc2N)n1cnc2c1nc([nH]c2=O)N)n1ccc(nc1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1ccc(nc1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1cnc2c1ncnc2N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1ccc(nc1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1ccc(nc1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1ccc(nc1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)n1cnc2c1ncnc2N)O
| StdInChI          = InChI=1S/C192H244N75O98P19S19/c1-76-40-256(190(286)245-169(76)270)136-30-89(357-376(299,395)314-50-106-84(25-131(334-106)251-15-7-122(196)230-185(251)281)351-370(293,389)312-49-105-87(28-134(333-105)254-18-10-125(199)233-188(254)284)355-374(297,393)323-59-115-97(38-145(343-115)266-74-225-154-167(266)238-180(208)243-175(154)276)364-381(304,400)319-55-111-90(31-137(339-111)257-41-77(2)170(271)246-191(257)287)356-375(298,394)313-46-102-81(22-128(330-102)248-12-4-119(193)227-182(248)278)348-366(289,385)308-44-100-79(269)20-127(328-100)259-67-218-147-156(201)210-63-214-160(147)259)110(338-136)54-318-380(303,399)359-92-33-139(260-68-219-148-157(202)211-64-215-161(148)260)340-112(92)56-320-373(296,392)354-88-29-135(255-19-11-126(200)234-189(255)285)336-108(88)52-316-379(302,398)363-96-37-144(265-73-224-153-166(265)237-179(207)242-174(153)275)346-118(96)62-326-384(307,403)365-98-39-146(267-75-226-155-168(267)239-181(209)244-176(155)277)344-116(98)60-324-377(300,396)358-91-32-138(258-42-78(3)171(272)247-192(258)288)337-109(91)53-317-371(294,390)352-85-26-132(252-16-8-123(197)231-186(252)282)335-107(85)51-315-378(301,397)362-95-36-143(264-72-223-152-165(264)236-178(206)241-173(152)274)345-117(95)61-325-383(306,402)361-94-35-141(262-70-221-150-159(204)213-66-217-163(150)262)342-114(94)58-322-382(305,401)360-93-34-140(261-69-220-149-158(203)212-65-216-162(149)261)341-113(93)57-321-372(295,391)353-86-27-133(253-17-9-124(198)232-187(253)283)332-104(86)48-311-369(292,388)350-83-24-130(250-14-6-121(195)229-184(250)280)331-103(83)47-310-368(291,387)349-82-23-129(249-13-5-120(194)228-183(249)279)329-101(82)45-309-367(290,386)347-80-21-142(327-99(80)43-268)263-71-222-151-164(263)235-177(205)240-172(151)273/h4-19,40-42,63-75,79-118,127-146,268-269H,20-39,43-62H2,1-3H3,(H,289,385)(H,290,386)(H,291,387)(H,292,388)(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H,299,395)(H,300,396)(H,301,397)(H,302,398)(H,303,399)(H,304,400)(H,305,401)(H,306,402)(H,307,403)(H2,193,227,278)(H2,194,228,279)(H2,195,229,280)(H2,196,230,281)(H2,197,231,282)(H2,198,232,283)(H2,199,233,284)(H2,200,234,285)(H2,201,210,214)(H2,202,211,215)(H2,203,212,216)(H2,204,213,217)(H,245,270,286)(H,246,271,287)(H,247,272,288)(H3,205,235,240,273)(H3,206,236,241,274)(H3,207,237,242,275)(H3,208,238,243,276)(H3,209,239,244,277)/t79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,366?,367?,368?,369?,370?,371?,372?,373?,374?,375?,376?,377?,378?,379?,380?,381?,382?,383?,384?/m0/s1
| StdInChIKey       = ZMJWRJKGPUDEOX-LMXUULCNSA-N
}}

'''Alicaforsen''' is an [[antisense]] oligonucleotide therapeutic that targets the [[messenger RNA]] for the production of human [[ICAM-1]] protein.<ref>{{cite web|title=Alicaforsen|url=http://adisinsight.springer.com/drugs/800003842|publisher=AdisInsight|accessdate=28 April 2017|language=en}}</ref>   It was discovered by [[Ionis Pharmaceuticals]] (formerly Isis Pharmaceuticals) and as of 2017 was under development by Atlantic Healthcare for [[pouchitis]] in an [[enema]] formulation.

==Pharmacology==
ICAM-1 promotes the [[extravasation]] and activation of [[leukocytes]] (white blood cells), which is part of the [[inflammation]] process.<ref name=Marafini2015rev/>  Alicaforsen inhibits the activity of [[ICAM-1]] protein by degrading [[mRNA]] coding for it via an [[RNase-H]] based mechanism.<ref name=Marafini2015rev>{{cite journal|first1=I|last1=Marafini|last2=Di Fusco |first2=D|last3=Calabrese|first3=E|last4=Sedda|first4=S|last5=Pallone|first5=F|last6=Monteleone|first6=G|title=Antisense approach to inflammatory bowel disease: prospects and challenges.|journal=Drugs|date=May 2015|volume=75|issue=7|pages=723–30|doi=10.1007/s40265-015-0391-0|pmid=25911184}}</ref>

It appears to have better efficacy as a [[topical medication]] than via [[systemic administration]] which is typical of antisense drugs.<ref name=Marafini2015rev/>

== Chemistry==
Alicaforsen is a 20 unit phosphorothioate modified antisense [[oligonucleotide]].<ref>{{cite journal|title=Recommended INN List 47|journal=WHO Drug Information|date=2002|volume=16|issue=1|url=http://www.who.int/medicines/publications/druginformation/innlists/PL85.pdf?ua=1}}</ref>

== History ==
Alicaforsen was discovered and initially developed by Isis Pharamaceuticals,<ref name=Drugs2001/> which changed its name to [[Ionis Pharmaceuticals]] in 2015.

Isis partnered on development of alicaforsen with [[Boehringer Ingelheim]] starting in 1995; that deal ended in 1999, after each of IV and subcutaneously delivered alicaforsen failed in phase III trials for [[Crohn's disease]] and development of those formulations in that indication was terminated; development for [[rheumatoid arthritis]] was terminated the same year and development in kidney transplant apparently ceased as well at that time.<ref name=Drugs2001>{{cite journal|last1=Gewirtz|first1=AT|last2=Sitaraman|first2=S|title=Alicaforsen. Isis Pharmaceuticals.|journal=Current opinion in investigational drugs (London, England : 2000)|date=October 2001|volume=2|issue=10|pages=1401–6|pmid=11890355}}</ref>

The company reformulated alicaforsen as an [[enema]] and three small trials were published between 2004 and 2006, an open label trial in chronic [[pouchitis]] and two randomized trials in [[ulcerative colitis]] (UC); in the UC trials the drug missed its primary endpoint of improvements at 6 weeks, but showed a better effect in the longer term (between 18 and 30 weeks).<ref name=Marafini2015rev/>

Alicaforsen was licensed to Atlantic Healthcare in 2007.<ref>{{cite web|title=Press Release: Atlantic Healthcare Completes Acquisition of ICAM-1 Portfolio of Late Stage Anti-inflammatory Drugs {{!}} Evaluate|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=123440|publisher=Atlantic Healthcare via Evaluate|date=2 April 2007}}</ref>

The use of the enema formulation of alicaforsen to treat pouchitis was granted [[orphan drug]] status in the US in 2008<ref>{{cite web|title=Alicaforsen US Orphan designation|url=http://www.orpha.net/consor/cgi-bin/Drugs_Search.php?lng=EN&data_id=64847&search=Drugs_Search_Simple&data_type=Status&Typ=Sub|publisher=Orphanet|accessdate=28 April 2017|language=en}}</ref> and received the same in Europe in 2009.<ref>{{cite web|title=EU/3/09/641 Orphan drug designation|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000606.jsp&mid=WC0b01ac058001d12b|publisher=European Medicines Agency|language=en|date=9 June 2009}}</ref>  As of April 2017 the enema formulation of alicaforsen for pouchitis had received [[Fast track (FDA)|FDA Fast Track]] designation and was in a Phase III trial.<ref>{{cite web|title=Alicaforsen (AP 1007) - Product Profile|url=https://bciq.biocentury.com/products/ISIS_2302|publisher=BioCentury|accessdate=28 April 2017}}</ref>

== References ==
{{reflist}}

==Further reading==
* 2013  meta-analysis authored by scientists who work for or were funded by Atlantic:  {{cite journal|last1=Vegter|first1=S|last2=Tolley|first2=K|last3=Wilson Waterworth|first3=T|last4=Jones|first4=H|last5=Jones|first5=S|last6=Jewell|first6=D|title=Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.|journal=Alimentary pharmacology & therapeutics|date=August 2013|volume=38|issue=3|pages=284–93|doi=10.1111/apt.12369|pmid=23750909|url=http://onlinelibrary.wiley.com/doi/10.1111/apt.12369/full}}

[[Category:Drugs acting on the gastrointestinal system and metabolism]]